Neumora Therapeutics (NMRA) Accumulated Depreciation & Amortization (2022 - 2025)

Neumora Therapeutics' Accumulated Depreciation & Amortization history runs 4 years deep, the most recent figure standing at $187000.0 for Q4 2025.

• In Q4 2025, Accumulated Depreciation & Amortization fell 90.87% year-over-year to $187000.0; the TTM figure through Dec 2025 stood at $187000.0 (down 90.87% YoY), while the FY2025 annual figure was $187000.0, down 90.87% from the prior year.
• Accumulated Depreciation & Amortization was $187000.0 for Q4 2025 at Neumora Therapeutics, down from $2.0 million in the prior quarter.
• In the past five years, Accumulated Depreciation & Amortization ranged from a high of $2.0 million in Q4 2024 to a low of $187000.0 in Q4 2025.
• Historically, Accumulated Depreciation & Amortization has averaged $1.1 million across 4 years, with a median of $990500.0 in 2022.
• The sharpest annual moves came in 2023 and 2025: Accumulated Depreciation & Amortization surged 162.82% in 2023, then plunged 90.87% in 2025.
• A 4-year view of Accumulated Depreciation & Amortization shows it stood at $546000.0 in 2022, then soared by 162.82% to $1.4 million in 2023, then surged by 42.79% to $2.0 million in 2024, then slumped by 90.87% to $187000.0 in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $187000.0 (Q4 2025), $2.0 million (Q4 2024), and $1.4 million (Q4 2023), per Business Quant data.